title: Asenapine.
abstract: Asenapine is a novel psychopharmacological agent that binds with high affinity and specificity to numerous dopamine, serotonin, noradrenaline (norepinephrine) and histamine receptor subtypes. It is being developed for the treatment of schizophrenia and bipolar mania. In two randomized, controlled trials of asenapine monotherapy and in one randomized, controlled trial of adjunctive asenapine therapy in adult patients with bipolar I disorder, sublingual asenapine produced significantly greater reductions from baseline than placebo in clinician-assessed Young Mania Rating Scale (YMRS) total score at 3 weeks. In two randomized, controlled trials in adult patients with acute schizophrenia, treatment with asenapine reduced from baseline the clinician-assessed Positive and Negative Syndrome Scale (PANSS) total score to a significantly greater extent than placebo at 6 weeks. In schizophrenic patients with predominant, persistent, negative symptoms, asenapine at 26 weeks reduced the Negative Symptom Assessment (NSA-16) total score from baseline to an extent similar to that observed with olanzapine. Sublingual asenapine was generally well tolerated in clinical trials, with most treatment-emergent adverse events being of mild to moderate severity. Incidence rates of clinically significant weight gain, extrapyramidal symptoms, hyperprolactinaemia and alterations in glucose or lipid metabolism were generally low.
authors.affiliation: Wolters Kluwer Health, Adis, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand.
authors.forename: Juliane
authors.initials: J
authors.lastname: Weber
authors.forename: Paul L
authors.initials: PL
authors.lastname: McCormack
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; C522667:asenapine
references.citation: Psychopharmacology (Berl). 2008 May;198(1):103-11
references.pmid: 18297468
references.citation: Psychopharmacol Bull. 2007;40(2):41-53
references.pmid: 17514185
references.citation: Pharmacoeconomics. 2008;26(2):149-62
references.pmid: 18198934
references.citation: Psychopharmacology (Berl). 1997 Jun;131(4):339-45
references.pmid: 9226735
references.citation: N Engl J Med. 2005 Sep 22;353(12):1286-8
references.pmid: 16172204
references.citation: Synapse. 2009 May;63(5):413-20
references.pmid: 19177511
references.citation: Pharmacoeconomics. 2005;23(6):583-94
references.pmid: 15960554
references.citation: Drugs. 2008;68(16):2269-92
references.pmid: 18973393
references.citation: Eur Neuropsychopharmacol. 2009 Mar;19(3):177-87
references.pmid: 19116183
references.citation: J Psychopharmacol. 2010 Mar;24(3):341-8
references.pmid: 18719049
references.citation: N Engl J Med. 2005 Sep 22;353(12):1209-23
references.pmid: 16172203
references.citation: J Psychopharmacol. 2009 Jan;23(1):65-73
references.pmid: 18308814
references.citation: CNS Drugs. 2006;20(5):389-409
references.pmid: 16696579
references.citation: Psychopharmacology (Berl). 2009 Jun;204(2):251-64
references.pmid: 19198810
references.citation: Psychopharmacology (Berl). 2008 Feb;196(3):417-29
references.pmid: 17940749
references.citation: J Clin Psychiatry. 2007 Oct;68(10):1492-500
references.pmid: 17960962
references.citation: Neuropsychopharmacology. 2008 Nov;33(12):2934-45
references.pmid: 18418367